Trial Profile
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2022
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary fibrosis; Pulmonary hypertension; Sarcoidosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Bellerophon Therapeutics
- 12 May 2022 According to a Bellerophon Therapeutics media release, data will be presented at the upcoming American Thoracis Society (ATS) 2022 International Conference.
- 11 May 2022 Status changed from active, no longer recruiting to completed as per Bellerophon Therapeutics media release.
- 07 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.